GRM5 and neurodegenerative disease: Taken together, these findings suggest that the inhibition of astrocytic mGlu5 may lead to a reduction in the neurotoxic inflammatory state seen in neurodegenerative disease, thereby contributing to the disease-modifying effects seen in rodent models after mGlu5 NAM treatment.